ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Ophthalmology · Am J Ophthalmol · 2025-12-11

RCT in 42 patients with chronic central serous chorioretinopathy without CNVM (39 analysed): >20% macular thickness reduction at 1 month in 77.27% with intravitreal brolucizumab vs 37.5% of controls (p=.01); visual acuity change was not significant.

RCTn = 42
Ramamurthy et al. A Randomized-Controlled Trial of the Efficacy, Safety and Tolerability of Intravitreal Brolucizumab in Patients With Chronic Central Serous Chorioretinopathy With Persistent Fluid in the Absence of Choroidal Neovascular Membrane-BRICS Trial Report II

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.